Literature DB >> 31290667

Predicting the Affinity of Peptides to Major Histocompatibility Complex Class II by Scoring Molecular Dynamics Simulations.

Rodrigo Ochoa1, Alessandro Laio2,3, Pilar Cossio1,4.   

Abstract

Predicting the binding affinity of peptides able to interact with major histocompatibility complex (MHC) molecules is a priority for researchers working in the identification of novel vaccines candidates. Most available approaches are based on the analysis of the sequence of peptides of known experimental affinity. However, for MHC class II receptors, these approaches are not very accurate, due to the intrinsic flexibility of the complex. To overcome these limitations, we propose to estimate the binding affinity of peptides bound to an MHC class II by averaging the score of the configurations from finite-temperature molecular dynamics simulations. The score is estimated for 18 different scoring functions, and we explored the optimal manner for combining them. To test the predictions, we considered eight peptides of known binding affinity. We found that six scoring functions correlate with the experimental ranking of the peptides significantly better than the others. We then assessed a set of techniques for combining the scoring functions by linear regression and logistic regression. We obtained a maximum accuracy of 82% for the predicted sign of the binding affinity using a logistic regression with optimized weights. These results are potentially useful to improve the reliability of in silico protocols to design high-affinity binding peptides for MHC class II receptors.

Year:  2019        PMID: 31290667     DOI: 10.1021/acs.jcim.9b00403

Source DB:  PubMed          Journal:  J Chem Inf Model        ISSN: 1549-9596            Impact factor:   4.956


  8 in total

1.  HLA-Arena: A Customizable Environment for the Structural Modeling and Analysis of Peptide-HLA Complexes for Cancer Immunotherapy.

Authors:  Dinler A Antunes; Jayvee R Abella; Sarah Hall-Swan; Didier Devaurs; Anja Conev; Mark Moll; Gregory Lizée; Lydia E Kavraki
Journal:  JCO Clin Cancer Inform       Date:  2020-07

2.  In Vitro Anti-Inflammatory Activity of Three Peptides Derived from the Byproduct of Rice Processing.

Authors:  Tingmin Qu; Shuwen He; Ce Ni; Ying Wu; Zhou Xu; Mao-Long Chen; Honghui Li; Yunhui Cheng; Li Wen
Journal:  Plant Foods Hum Nutr       Date:  2022-04-21       Impact factor: 3.921

3.  Computational Evolution Protocol for Peptide Design.

Authors:  Rodrigo Ochoa; Miguel A Soler; Ivan Gladich; Anna Battisti; Nikola Minovski; Alex Rodriguez; Sara Fortuna; Pilar Cossio; Alessandro Laio
Journal:  Methods Mol Biol       Date:  2022

4.  Protocol for iterative optimization of modified peptides bound to protein targets.

Authors:  Rodrigo Ochoa; Pilar Cossio; Thomas Fox
Journal:  J Comput Aided Mol Des       Date:  2022-10-19       Impact factor: 4.179

5.  Multiple-Allele MHC Class II Epitope Engineering by a Molecular Dynamics-Based Evolution Protocol.

Authors:  Rodrigo Ochoa; Victoria Alves Santos Lunardelli; Daniela Santoro Rosa; Alessandro Laio; Pilar Cossio
Journal:  Front Immunol       Date:  2022-04-27       Impact factor: 8.786

6.  Combining Three-Dimensional Modeling with Artificial Intelligence to Increase Specificity and Precision in Peptide-MHC Binding Predictions.

Authors:  Michelle P Aranha; Yead S M Jewel; Robert A Beckman; Louis M Weiner; Julie C Mitchell; Jerry M Parks; Jeremy C Smith
Journal:  J Immunol       Date:  2020-09-02       Impact factor: 5.422

7.  Computational Evolution of Beta-2-Microglobulin Binding Peptides for Nanopatterned Surface Sensors.

Authors:  Abimbola Feyisara Adedeji Olulana; Miguel A Soler; Martina Lotteri; Hendrik Vondracek; Loredana Casalis; Daniela Marasco; Matteo Castronovo; Sara Fortuna
Journal:  Int J Mol Sci       Date:  2021-01-15       Impact factor: 5.923

8.  Impact of Structural Observables From Simulations to Predict the Effect of Single-Point Mutations in MHC Class II Peptide Binders.

Authors:  Rodrigo Ochoa; Roman A Laskowski; Janet M Thornton; Pilar Cossio
Journal:  Front Mol Biosci       Date:  2021-03-30
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.